ESR1 and breast cancer: It may be hypothesized that the loss of MutL expression could activate HER2 without receptor overexpression; consequently, MutL loss has been proposed as a marker to stratify ER+/HER2-negative BC patients who are probably responsive to anti-HER agents [89].